Headlines
Home » BioMedWire Client Partners

BioMedWire Spotlight Company

Annovis Bio Inc. (NYSE: ANVS)

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

View Profile

BioMedWire Spotlight Company

Clene Inc. (NASDAQ: CLNN)

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

View Profile

BioMedWire Spotlight Company

Aditxt Inc. (NASDAQ: ADTX)

Aditxt Inc. is a innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

View Profile

BioMedWire Spotlight Company

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

View Profile

BioMedWire Client Partners

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050

BioMedWire
BioMedWire

1728 Ocean Ave.
Suite BMW-276
San Francisco, CA 94112-1737
(415) 949-5050

Company Search
Get Quote
Site Search

Copyright © . BioMedWire / 1728 Ocean Ave. Suite BMW-276, San Francisco, CA 94112-1737 (415) 949-5050 / Disclaimers